

Sun Pharmaceutical Industries Limited
Sun House, Plot No. 201 B/1,
Western Express Highway, Goregaon (E),
Mumbai – 400 063, Maharashtra, INDIA.
Tel.: (91-22) 4324 4324
Fax: (91-22) 4324 4343
Website: www.sunpharma.com
Email: secretarial@sunpharma.com
CIN: L24230GJ1993PLC019050



21 March 2026

National Stock Exchange of India Limited
Scrip Symbol: SUNPHARMA

BSE Limited
Scrip Code: 524715

Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Press Release

Enclosed herewith is a copy of the press release titled “Sun Pharma launches its semaglutide injection under the brand names, Noveltreat and Sematrinity in India,” which shall be released after this intimation.

For **Sun Pharmaceutical Industries Limited**

(Anoop Deshpande)
Company Secretary and Compliance Officer
ICSI Membership No.: A23983

Sun Pharmaceutical Industries Limited
Sun House, Plot No. 201 B/1,
Western Express Highway, Goregaon (E),
Mumbai – 400 063, Maharashtra, INDIA.
Tel.: (91-22) 4324 4324
Fax: (91-22) 4324 4343
Website: www.sunpharma.com
Email: secretarial@sunpharma.com
CIN: L24230GJ1993PLC019050



FOR IMMEDIATE RELEASE

Sun Pharma launches its semaglutide injection under the brand names, Noveltreat and Sematrinity in India

Mumbai, India, March 21, 2026: Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, “Sun Pharma” and includes its subsidiaries and/or associate companies) today announced the launch of its semaglutide injection under the brand names Noveltreat and Sematrinity in India, in all strengths. Noveltreat is indicated for chronic weight management in adults as an adjunct to a reduced calorie diet & increased physical activity and is available in five dose strengths – 0.25 mg/0.5 mL, 0.5 mg/0.5 mL, 1 mg/0.5 mL, 1.7 mg/0.75 mL, and 2.4 mg/0.75 mL. Sematrinity is indicated for treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet & exercise and is available in two dose strengths – 2 mg/1.5 mL and 4 mg/3 mL. Priced significantly lower than the innovator brand, weekly therapy costs, from initiation to the highest dose, range from approximately ₹900 to ₹2,000 for Noveltreat and ₹750 to ₹1,300 for Sematrinity, supporting greater affordability.

Commenting on the launch, Kirti Ganorkar, Managing Director, Sun Pharmaceutical Industries Ltd, said, “With the launch of Noveltreat and Sematrinity, our endeavour is to provide a high-quality, affordable therapy to a wider patient community in India. We are offering a comprehensive range, backed by our decades of expertise in manufacturing complex medicines. To further support patients, we are also introducing a holistic patient support program intended to guide them throughout their treatment journey”.

Noveltreat’s prefilled pen uses a concealed needle to help ease injection fear and improve both handling safety and dosing accuracy. Sematrinity comes in a multi-dose pen format that offers flexible dosing, with a smooth dialer that enables accurate dose delivery. The easy-to-use, pre-filled pens, developed by leading global pharmaceutical device suppliers, are manufactured in Europe.

About GLP-1 class of drugs

GLP-1 agonists are a class of medications utilized to treat type 2 diabetes mellitus (T2DM) and obesity.ⁱ These therapies including semaglutide, are considered as highly effective treatment options for people with T2DM and obesity, while reducing cardiovascular and renal morbidity and mortality.ⁱⁱ

Obesity and diabetes

As per National Family Health Survey-5 (NFHS-5), almost one in four Indians between the age group 15-49 is now overweight or obese.ⁱⁱⁱ Obesity is associated with several comorbidities, including, but not limited to, metabolic and cardiovascular consequences, and increased risk of cancer, morbidity and mortality.^{iv} There is an urgent need to mandate timely screening, timely treatment with effective therapies and lifestyle interventions, and maintaining weight loss in these patients to ensure enhanced treatment outcomes.ⁱⁱⁱ

As per the ICMR INDIAB 17 study published in 2023 an estimated 101.3 million people had diabetes in India.^v Diabetic patients are at risk of complications such as blindness, kidney failure, amputations, and heart attacks.^{vi} About 64% of patients in India do not reach their HbA1c targets.^{vii} Therefore, there

Sun Pharmaceutical Industries Limited
Sun House, Plot No. 201 B/1,
Western Express Highway, Goregaon (E),
Mumbai – 400 063, Maharashtra, INDIA.
Tel.: (91-22) 4324 4324
Fax: (91-22) 4324 4343
Website: www.sunpharma.com
Email: secretarial@sunpharma.com
CIN: L24230GJ1993PLC019050



is need for a comprehensive approach towards managing diabetes, including newer and more efficacious therapies.

About Sun Pharmaceutical Industries Limited. (CIN - L24230GJ1993PLC019050)

Sun Pharma is the world’s leading specialty generics company with a presence in Innovative Medicines, Generics and Consumer Healthcare products. It is the largest pharmaceutical company in India and is a leading generic company in the US as well as Global Emerging Markets. Sun’s high growth Global Innovative Medicines portfolio spans innovative products in dermatology, ophthalmology, and onco-dermatology and accounts for about 20% of company sales. The company’s vertically integrated operations deliver high-quality medicines, trusted by physicians and consumers in over 100 countries. Its manufacturing facilities are spread across five continents. Sun Pharma is proud of its multi-cultural workforce drawn from over 50 nations. “For further information, please visit www.sunpharma.com and follow us on LinkedIn & X (Formerly Twitter).”

ⁱ Collins L, Costello RA. Glucagon-Like Peptide-1 Receptor Agonists. [Updated 2024 Feb 29]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK551568/>

ⁱⁱ Drucker, D.J. GLP-1-based therapies for diabetes, obesity and beyond. Nat Rev Drug Discov 24, 631–650 (2025). <https://doi.org/10.1038/s41573-025-01183-8>

ⁱⁱⁱ Kalra S, et al. Defining and Diagnosing Obesity in India: A Call for Advocacy and Action. J Obes. 2023; 4178121. doi: 10.1155/2023/4178121. PMID: 38026823; PMCID: PMC10645500

^{iv} Ray, S, et al. An overview of therapeutic options of obesity management in India: the Integrated Diabetes and Endocrinology Academy (IDEA) 2023 Congress update. Expert Review of Clinical Pharmacology, 2024; 17(4), 349–362. <https://doi.org/10.1080/17512433.2024.2330468>

^v ICMR-INDIAB-17. Metabolic non-communicable disease health report of India: the ICMR-INDIAB national cross-sectional study (ICMR-INDIAB-17). Lancet Diabetes Endocrinol. 2023 Jul;11(7):474-489

^{vi} Mohan V, Tiwaskar M. The Unrelenting Epidemic of Diabetes in India: Do the Numbers Matter? J Assoc Physicians India 2025;73(5):12-13

^{vii} Anjana RM et al. Achievement of guideline recommended diabetes treatment targets and health habits in people with self-reported diabetes in India (ICMR-INDIAB-13): a national cross-sectional study. Lancet Diabetes Endocrinol. 2022 Jun;10(6):430-441

Disclaimer - This press release is for informational purposes only and not for any kind of promotion. Both Noveltreat and Sematrinity are prescription medicines and must be used only under the supervision of a Registered Medical Practitioner. All clinical decisions regarding treatment should be based on a patient’s individual health profile and approved prescribing information available to qualified healthcare professionals. Patients should consult their treating physician for all medical decisions.

Contacts: Sun Pharma

Investors

Dr. Abhishek Sharma
Tel +91 22 4324 4324, Xtn 2929
Tel (D) +91 22 4324 2929
Mobile +91 98196 86016
E mail abhi.sharma@sunpharma.com

Media

Gaurav Chugh
Tel +91 22 4324 4324, Xtn 5373
Tel (D) +91 22 4324 5373
Mobile +91 98104 71414
E mail gaurav.chugh@sunpharma.com